PDCD1 and cancer: Immune checkpoint blocking of anti-PD-1 or anti-PD-L1 antibodies is the latest treatment for a variety of cancers, including non-small cell lung cancer (19–21), melanoma (22), bladder cancer (23), and kidney cancer (24).